Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imiquimod intravesicular - UroGen Pharma

Drug Profile

Imiquimod intravesicular - UroGen Pharma

Alternative Names: TMX-101; UGN 201; Vesimune

Latest Information Update: 16 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telormedix
  • Developer UroGen Pharma
  • Class Adjuvants; Aminoquinolines; Antineoplastics; Antivirals; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bladder cancer

Most Recent Events

  • 31 Jul 2022 UroGen Pharma concludes the collaboration with MD Anderson for non clinical development of imiquimod + zalifrelimab as the research objectives achieved before July 2022
  • 23 May 2022 UroGen Pharma initiates phase I trial for Bladder cancer (Combination therapy, Recurrent) in USA (Intravesicular) (NCT05375903)
  • 22 Mar 2021 Phase I/II development is ongoing for non-muscle invasive Bladder cancer in Netherlands and Germany (UroGen Pharma pipeline, March 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top